The American Society of Hematology Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT03948867
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

American Society of Hematology | The American Society of Hematology

Active Ingredients

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

hydroxyurea (hydrea) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Sickle Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2